Epithelial ovarian cancer (EOC) is the fourth leading cause of cancer-related death in women in the United States and is the leading cause of gynecologic cancer death. A major limitation in the treatment of ovarian cancer is the widespread development of resistance to a broad range of chemotherapeutic agents. This is confounded by the lack of means to rapidly detect chemo-response. The induction of apoptosis is one of the key mechanisms by which chemotherapeutic agents exert their cytotoxicity. This proposal is based on the hypothesis that therapeutic modulation of the factors that induce or block apoptosis may represent a specific approach for ovarian cancer therapy. In addition, we hypothesize that downstream products of the apoptotic cascade can be detected and measured in the serum of patients and may serve as markers for chemo- response. The main objectives of this proposal are: 1) to further enhance our understanding of the main regulatory factors of apoptosis in ovarian cancer cells, and 2) to develop a means to rapidly monitor response to treatment. Specifically we propose:
Aim 1. To determine the regulators and effectors of caspase-2 in the process of chemo-response in EOC cells;
Aim 2. To determine the molecular mechanisms regulating XIAP degradation and cleavage during chemotherapy-induced apoptosis in EOC cells;
and Aim 3. To identify markers for the rapid monitoring of response to chemotherapy. Understanding the molecular mechanism by which cancer cells become resistant to apoptosis will allow us to modulate the factor(s) controlling the apoptotic cascade and may provide a specific approach for new cancer therapies. In addition, the identification of sensitive and specific markers of chemo-response and the development of a rapid blood test that can be used for rapid point-of-care analysis of therapeutic response will not only enable individual tailoring of treatment but will also identify patients who are not responsive, hence sparing them the ill-effects of chemotherapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA118678-05
Application #
8118455
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Arya, Suresh
Project Start
2007-08-13
Project End
2013-07-31
Budget Start
2011-08-01
Budget End
2013-07-31
Support Year
5
Fiscal Year
2011
Total Cost
$305,017
Indirect Cost
Name
Yale University
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Yang-Hartwich, Y; Soteras, M G; Lin, Z P et al. (2015) p53 protein aggregation promotes platinum resistance in ovarian cancer. Oncogene 34:3605-16
Alvero, Ayesha B; Montagna, Michele K; Sumi, Natalia J et al. (2014) Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors. Oncotarget 5:8703-15
Sumi, Natalia J; Lima, Eydis; Pizzonia, John et al. (2014) Murine model for non-invasive imaging to detect and monitor ovarian cancer recurrence. J Vis Exp :e51815
Liu, Ming; Mor, Gil; Cheng, Huan et al. (2013) High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer. Reprod Sci 20:605-15
Chefetz, Ilana; Alvero, Ayesha B; Holmberg, Jennie C et al. (2013) TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence. Cell Cycle 12:511-21
Craveiro, Vinicius; Yang-Hartwich, Yang; Holmberg, Jennie C et al. (2013) Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Med 2:751-62
Yin, G; Alvero, A B; Craveiro, V et al. (2013) Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene 32:39-49
Joo, Won Duk; Visintin, Irene; Mor, Gil (2013) Targeted cancer therapy--are the days of systemic chemotherapy numbered? Maturitas 76:308-14
Alvero, Ayesha B; Montagna, Michele K; Craveiro, Vinicius et al. (2012) Distinct subpopulations of epithelial ovarian cancer cells can differentially induce macrophages and T regulatory cells toward a pro-tumor phenotype. Am J Reprod Immunol 67:256-65
Pizzonia, John; Holmberg, Jennie; Orton, Sean et al. (2012) Multimodality animal rotation imaging system (Mars) for in vivo detection of intraperitoneal tumors. Am J Reprod Immunol 67:84-90

Showing the most recent 10 out of 27 publications